Targeting Inflammatory Pathways: Implementing Personalized Approaches for Your Severe Asthma Patients (EXT)

Patients with inadequately controlled, severe persistent asthma are at risk for exacerbations, hospitalization, and death and often have impaired quality of life. In a US survey of asthma patients, more than half reported that their disease is uncontrolled. Some patients with severe asthma have persistent daily symptoms and exacerbations despite high doses of inhaled steroids and additional treatment. The increasing prevalence of asthma highlights the need for improved diagnosis and more aggressive and effective treatment. As the scientific understanding of airway inflammation and narrowing continues to evolve, findings of clinical trials evaluating new treatments show promise for the management of severe asthma.

Release Date: 12/15/2015
Expiration Date: 12/14/2016

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Commercial Support: This program is supported by an independant educational grant from Teva Pharmaceutical Industries Ltd.

Target Audience

Allergists/immunologists, pulmonologists, primary care and internal medicine physicians, and other healthcare clinicians involved in the treatment of patients with severe asthma.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss the role of inflammatory mediators in the pathogenesis of asthma
  • Implement stepwise, personalized approaches provided by national and global treatment guidelines and recommendations, such as the NAEPP EPR-3 and GINA, to control symptoms, reduce exacerbations and improve the quality of life of severe asthma patients
  • Utilize appropriate treatment strategies for patients with severe persistent asthma whose symptoms are poorly controlled on inhaled corticosteroids
  • Analyze the safety and efficacy of emerging treatment strategies that are currently being evaluated for poorly controlled asthma
Additional information
Disclosure: 

PLANNING COMMITTEE
Bobby Q. Lanier, MD, FACAAI
Executive Medical Director
American College of Allergy, Asthma & Immunology
Clinical Professor of Pediatrics
University of North Texas Health Science Center
Fort Worth, TX

Supported/Contracted Research: Merck, Novartis, Teva; Speaker: Genentech, Merck

Program Chair and Moderator
Bradley E. Chipps, MD, FACAAI

Medical Director, Respiratory Therapy and Cystic Fibrosis Center
Sutter Medical Center
Capital Allergy & Respiratory Disease Center
Sacramento, CA
Consultant/Advisor, Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, Novartis

FACULTY

Rohit K. Katial, MD, FACAAI
Professor of Medicine
Associate Vice President of Clinical Research & Industry Relationships
Co-Director, Asthma Institute
Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics
Department of Medicine
National Jewish Health
Denver, CO
Consultant/Advisor: AstraZeneca, GlaxoSmithKline, Meda, Teva; Speaker: AstraZeneca, Meda, Teva; Supported/Contracted Research: AstraZeneca, Teva

Stephen P. Peters, MD, PhD
Thomas H. Davis Chair in Pulmonary Medicine
Chief, Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases
Wake Forest School of Medicine
Executive Director, Respiratory Service Line, Wake Forest Baptist Health
Wake Forest Baptist Medical Center
Winston-Salem, NC
Consultant/Advisor: Array Biopharma, Aerocrine, Airsonett AB, AstraZeneca, Boehringer Ingelheim, Catalyst Biosciences, Experts in Asthma, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Ono, Pfizer, PPD, Quintiles, Sunovion, Teva and Theron; Speaker:
Merck; Supported/Contracted Research: American Lung Association, National Institutes of Health (NHLBI & NIAID), Actavis, Actelion, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen Biotech, Genentech, GlaxoSmithKline, MedImmune, Novartis and Sanofi

Education and Publishing Staff/Committee/Reviewers have no relevant financial relationships to disclose, except as may be listed above.

Course summary
Course opens: 
12/15/2015
Course expires: 
12/14/2016
Cost:
$0.00
Rating: 
0

PLANNING COMMITTEE
Bobby Q. Lanier, MD, FACAAI - Executive Medical Director - American College of Allergy, Asthma & Immunology. Clinical Professor of Pediatrics - University of North Texas Health Science Center - Fort Worth, TX. Supported/Contracted Research: Merck, Novartis, Teva; Speaker: Genentech, Merck. Program Chair and Moderator
Bradley E. Chipps, MD, FACAAI - Medical Director, Respiratory Therapy and Cystic Fibrosis Center, Sutter Medical Center. Capital Allergy & Respiratory Disease Center, Sacramento, CA. Consultant/Advisor, Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, Novartis
Rohit K. Katial, MD, FACAAI - Professor of Medicine, Associate Vice President of Clinical Research & Industry Relationships, Co-Director, Asthma Institute, Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics - Department of Medicine, National Jewish Health, Denver, CO. Consultant/Advisor: AstraZeneca, GlaxoSmithKline, Meda, Teva; Speaker: AstraZeneca, Meda, Teva; Supported/Contracted Research: AstraZeneca, Teva
Stephen P. Peters, MD, PhD - Thomas H. Davis Chair in Pulmonary Medicine, Chief, Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases - Wake Forest School of Medicine. Executive Director, Respiratory Service Line, Wake Forest Baptist Health, Wake Forest Baptist Medical Center, Winston-Salem, NC. Consultant/Advisor: Array Biopharma, Aerocrine, Airsonett AB, AstraZeneca, Boehringer Ingelheim, Catalyst Biosciences, Experts in Asthma, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Ono, Pfizer, PPD, Quintiles, Sunovion, Teva and Theron; Speaker: Merck; Supported/Contracted Research: American Lung Association, National Institutes of Health (NHLBI & NIAID), Actavis, Actelion,
Amgen, AstraZeneca, Boehringer Ingelheim, Janssen Biotech, Genentech, GlaxoSmithKline, MedImmune, Novartis and Sanofi
FACULTY
Education and Publishing Staff/Committee/Reviewers have no relevant financial relationships to
disclose, except as may be listed above.

Available Credit

Accreditation Period

Course opens: 
12/15/2015
Course expires: 
12/14/2016

Price

Cost:
$0.00
Please login or create an account to take this course.